Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Senseonics Holdings, Inc. (SENS) provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Senseonics is a medical technology company focused on the development and manufacturing of long-term implantable continuous glucose monitoring (CGM) systems, and its filings offer detailed insight into its financial condition, capital structure, and corporate actions.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and financial statements related to its Eversense 365 and Eversense E3 glucose monitoring products. Form 8-K current reports disclose material events, such as preliminary financial results, the implementation of a 1-for-20 reverse stock split, special stockholder meetings, and updates on commercialization plans and collaborations.
Investors can also review proxy materials, such as the DEF 14A definitive proxy statement for the special meeting of stockholders that authorized the reverse stock split and proportional reduction in authorized shares. In addition, a Form 25 filing documents the voluntary removal of Senseonics’ common stock from listing and registration on the NYSE American in connection with the transfer of its listing to the Nasdaq Global Select Market.
Through this page, users can follow how Senseonics reports on topics such as revenue updates, capital structure changes, and governance matters. Real-time updates from EDGAR ensure that new filings, including Forms 8-K, 10-Q, and 10-K, appear as they are submitted. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections, and clarify technical language, making it easier to understand how Senseonics’ regulatory disclosures relate to its long-term implantable CGM business.
For those researching SENS, this filings page serves as a central location to review the company’s official SEC documents, track its corporate history, and analyze how its medical technology operations and public company obligations intersect.
Senseonics Holdings (SENS) reported an insider purchase on Form 4. A reporting person who serves as President, CEO, and Director bought 17,210 shares of common stock on 11/07/2025 at a weighted average price of $5.87.
Following the transaction, the filer beneficially owns 661,085 shares, held directly. The company effected a 1-for-20 reverse stock split on October 17, 2025, and the reported share amounts reflect this adjustment. The price reflects multiple trades between $5.80 and $5.90.
Senseonics Holdings, Inc. filed its Q3 2025 10‑Q, reporting total revenue of $8.1 million, up from $4.3 million a year ago, and a net loss of $19.5 million. Gross profit was $3.5 million versus a gross loss in the prior year period.
The company ended the quarter with $111.0 million in unrestricted cash, cash equivalents and marketable securities. Management disclosed that substantial doubt exists regarding its ability to continue as a going concern, citing expected cash needs and covenant requirements under its amended loan agreement.
Senseonics amended its term loan facility on September 3, 2025, increasing capacity to $100.0 million (maturing September 3, 2029) with a minimum cash covenant. It also raised capital via a $57.5 million public offering and a concurrent $20.3 million private placement with Abbott in May, and established a $100.0 million at‑the‑market program in August. A 1‑for‑20 reverse stock split became effective on October 17, 2025. The company signed an MOU with Ascensia to transition Eversense commercialization back to Senseonics beginning January 1, 2026.
Senseonics Holdings, Inc. reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and provided details for a conference call to discuss results, corporate highlights, and outlook. The press release was furnished as Exhibit 99.1 to this report. The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Exchange Act.
Senseonics Holdings (SENS) approved a 1-for-20 reverse stock split and reduced authorized common shares to 70,000,000. The action is set by a Certificate of Amendment and becomes effective at 4:05 p.m. Eastern Time on October 17, 2025. At the effective time, every twenty issued and outstanding common shares will be combined into one share, with no change to par value.
The split triggers proportional adjustments to outstanding stock options, restricted stock units, warrants, and the share reserves under equity plans. Fractional shares will not be issued; stockholders otherwise entitled to a fraction will receive a cash payment instead. The reverse split applies to all holders proportionately and does not change any holder’s ownership percentage, aside from effects related to fractional shares. The common stock is expected to begin trading on a split-adjusted basis on the NYSE American on October 20, 2025 under the symbol SENS.
Senseonics Holdings director Douglas S. Prince received 19,673 shares of common stock on 10/01/2025 as payment under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. The shares were issued using the closing price of $0.413 on the NYSE American for that date, representing the reported cash-equivalent value of $8,124.95. After the issuance, the filing reports the reporting person beneficially owned 1,107,280 shares. The Form 4 was signed by an attorney-in-fact and filed on 10/03/2025.
Douglas A. Roeder, a director of Senseonics Holdings, Inc. (SENS), received 35,714 shares of common stock under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees. The shares were issued based on the NYSE American closing price of $0.413 per share on the transaction date, representing cash-equivalent compensation of $14,749.88. After this issuance, the reporting person beneficially owned 1,694,540 shares of the issuer’s common stock. The transaction is reported on a Form 4 and was filed by a single reporting person. The Form states the issuance was pursuant to the issuer’s director compensation policy and discloses the calculation used to determine the share amount.
Senseonics Holdings director Edward Fiorentino received 34,200 shares of common stock on 10/01/2025 under the company's non-employee director compensation policy. The shares were issued in lieu of a quarterly retainer; the filing states the number of shares equals $14,124.60 divided by the closing price of $0.413 per share on the NYSE American that day.
After the issuance, the reporting person beneficially owned 1,379,301 shares. The Form 4 was signed by attorney-in-fact Frederick T. Sullivan on 10/03/2025. The filing records this as a routine equity grant to a director under the disclosed compensation policy.
Senseonics Holdings, Inc. disclosed an insider transaction on a Form 4 showing a director received 31,174 shares of common stock on October 1, 2025. The shares were issued under the non-employee director compensation policy in lieu of quarterly retainer fees, calculated as $12,874.86 divided by the $0.413 closing price on that date.
Following the transaction, the director beneficially owned 1,294,175 shares, held directly.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
